Sector
PharmaceuticalsOpen
₹13.53Prev. Close
₹13.53Turnover(Lac.)
₹10.68Day's High
₹13.53Day's Low
₹13.2652 Week's High
₹27.1552 Week's Low
₹5.75Book Value
₹1.23Face Value
₹1Mkt Cap (₹ Cr.)
580.63P/E
69.79EPS
0.19Divi. Yield
017 Sep 2024
12:00 AM
BookCloser
30 Jul 2024
12:00 AM
EGM
29 Jan 2025
12:00 AM
Split
15 Sep 2024
12:00 AM
AGM
Announcement Date: 15 Sep, 2024
16 May 2025
12:00 AM
Board Meeting
Agenda : Audited Result
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 10.95 | 3.91 | 1.57 | 1.57 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 46.69 | 21.38 | 14.78 | 14.03 |
Net Worth | 57.64 | 25.29 | 16.35 | 15.6 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 11.84 | 5.65 | 5.34 | 5.13 |
yoy growth (%) | 109.3 | 5.9 | 4.02 | 6.46 |
Raw materials | -3 | -0.99 | -0.95 | -1.04 |
As % of sales | 25.33 | 17.5 | 17.79 | 20.29 |
Employee costs | -4.4 | -1.96 | -1.27 | -1.09 |
| Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 0.06 | 0.72 | 0.94 | 1.05 |
Depreciation | -1.47 | -0.96 | -0.73 | -0.46 |
Tax paid | -0.13 | -0.26 | -0.42 | -0.55 |
Working capital | 0.39 | 1.47 | 0.26 | 0.19 |
Other operating items |
| Y/e 31 Mar | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 109.3 | 5.9 | 4.02 | 6.46 |
Op profit growth | -6.61 | 2.11 | 10.28 | 24.06 |
EBIT growth | -90.08 | -26.76 | -6.95 | 15.17 |
Net profit growth | -92.29 | -12.12 | 4.55 | 321.93 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,678.3 | 94.02 | 4,02,680.39 | 2,000.46 | 0.95 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,612.15 | 79.46 | 1,75,531.81 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,464.85 | 24.02 | 1,18,307.2 | 1,485.4 | 1.09 | 4,254.47 | 397.44 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,173.95 | 56.38 | 1,07,416.07 | 474 | 1.01 | 2,385 | 224.33 |
Dr Reddys Laboratories Ltd DRREDDY | 1,251.75 | 19.53 | 1,04,452.95 | 1,200.7 | 0.64 | 5,546.3 | 345.81 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Dakshesh Shah
Executive Director
Payal Mehta
Independent Director
Bhoomiben Patel
Independent Director
Sarjeevan Singh
Independent Director
Sonal Deepalbhai Gandhi
Whole Time Director
Sanskruti Patel
Whole Time Director
Dhruvin Shah
Independent Director
Pinki Nirmal Sagar
Whole Time Director
Anar Jayesh Patel
Independent Director
Jitendra shah
Company Sec. & Compli. Officer
Arpita Kabraa
Independent Director
Ritu Kapoor
Whole Time Director
Sheetal Shah
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Shukra Pharmaceuticals Ltd
Summary
Shukra Pharmaceuticals Limited (Formerly known Relish Pharmaceuticals Limited) was established in March, 1993 and later on the Company name was changed from Relish Pharmaceuticals Limited to Shukra Pharmaceuticals Limited effective on September 22, 2016. The Company is presently engaged in the business of manufacturing and trading of pharmaceuticals formulations and laboratory testing. The company provides varieties of products to the clientele. Their product portfolio includes Antibiotics (Penicillin), Anti Biotics (Cephalosporin), Anti Biotics, Macrolides, Quinolones, Anti Bacterial, Anti Fungal, Anti Malarial, Anti Viral, Anti Protozoal, Anti Anthelmintic, Sedative and Tranquilliser, Anti Depressant, Anti Manic, Anti Emetic, Anti Ulcer, Beta Blockers, Diuretics, Analgesic, Analgesic (NASID), Muscle Relaxants, Anti Tuberculosis, Vitamin Products, Anti Allergics, Corticosteroids, Hyper and Hypoglycemic, Others.The company has four manufacturing divisions namely tablets (General and Beta Lactum) Capsules (General and Beta Lactum), Liquid and small volume parental. Their manufacturing unit is located at Rakanpur in Gujarat.The company customers include leading Manufacturers like Cadila Healthcare Limited (Zydus), Intas Pharmaceuticals Limited, Cadila Pharmaceuticals Limited, Makers Laboratories Limited, Agenta Pharma Limited etc.The company has assisted in the development and manufacture of a wide variety of drugs and dosage forms and potency variations for many prestigious p
Read More
What is the Shukra Pharmaceuticals Ltd share price today?
The Shukra Pharmaceuticals Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹13.26 today.
What is the Market Cap of Shukra Pharmaceuticals Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Shukra Pharmaceuticals Ltd is ₹580.63 Cr. as of 30 May ‘25
What is the PE and PB ratio of Shukra Pharmaceuticals Ltd?
The PE and PB ratios of Shukra Pharmaceuticals Ltd is 69.79 and 10.70 as of 30 May ‘25
What is the 52 Week High and Low of Shukra Pharmaceuticals Ltd?
The 52-week high/low is the highest and lowest price at which a Shukra Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Shukra Pharmaceuticals Ltd is ₹5.75 and ₹27.15 as of 30 May ‘25
What is the CAGR of Shukra Pharmaceuticals Ltd?
Shukra Pharmaceuticals Ltd's CAGR for 5 Years at 133.75%, 3 Years at 246.04%, 1 Year at 28.86%, 6 Month at 113.18%, 3 Month at -43.57% and 1 Month at -17.07%.
What is the shareholding pattern of Shukra Pharmaceuticals Ltd?
The shareholding pattern of Shukra Pharmaceuticals Ltd is as follows:
Promoters - 50.96 %
Institutions - 0.11 %
Public - 48.93 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.